HCPLive Network

Research Offers Hope for Treatment of Cocaine Addiction

Recent research may potentially lead to the development of the first pharmacological treatment for cocaine addiction.

The study was performed by investigators at the University of Wisconsin-Milwaukee (UWM); the report was coauthored by Devin Mueller, UWM assistant professor of psychology, and James Otis.

The researchers studied animals that were addicted to cocaine and discovered that propranolol, a beta blocker commonly used as a treatment for individuals suffering from hypertension and anxiety, also efficiently inhibits the brain from recovering memories connected to cocaine use.

Cocaine is known to be one of them most difficult drugs to cease taking. Roughly 80% of cocaine addicts who attempt to quit suffer from a relapse within six months.

According to Mueller, this research is the first occurrence of a therapeutic treatment being utilized in order to hinder the retrieval of memories associated with drug addiction, which is known to be connected to why numerous ex-addicts relapse.

"Right now, there are no FDA-approved medications that are known to successfully treat cocaine abuse, only those that are used to treat the symptoms of cocaine withdrawal, which are largely ineffective at preventing relapse,” stated Mueller.

Mueller went on to say that that the effects of propranolol on stimuli known to induce relapse were long-lasting in the animal models, and could possibly even be permanent. This held true even without subsequent doses.

In previous studies, propranolol has been found to relieve some of the brutal withdrawal symptoms recovering cocaine addicts suffer from.

A current treatment that is being used for recovering addicts is "exposure therapy" which aids them to restrain their drug-seeking behavior. Exposure therapy forces the patient to be frequently exposed to stimuli that provokes cravings but do not satisfy them.

Performed repeatedly over a period of time, exposure therapy results in the recovering addict experiencing a decrease in cravings for his or her drug of choice when confronted with the stimuli.

Exposure therapy has limited success, however.

Mueller believes that combing this therapy with the use of propranolol could most definitely increase its effectiveness, as previous studies have shown that recovering addicts who use propranolol to help ease withdrawal symptoms have also persisted with exposure therapy longer than patients without the drug.

But, Mueller cautions, propranolol was not tested for use with memory extinction.

Mueller added that the next step to developing a drug treatment for overcoming drug relapse is to figure out where in the brain propranolol works to mediate the retrieval of cocaine-associated memories.

The research, compiled into an article titled "Inhibition of β-Adrenergic Receptors Induces a Persistent Deficit in Retrieval of a Cocaine-Associated Memory Providing Protection against Reinstatement,” is published in the August issue of the journal Neuropsychopharmacology.
 

Further Reading
Omega-3 supplementation can help reduce behavioral issues in adolescents who may be particularly prone to oxytocin receptor gene methylation.
Patients are receiving medical implants that may not have been rigorously tested before or after their approval by the US Food and Drug Administration, two new studies contend. The findings were published online Sept. 29 in JAMA Internal Medicine.
For critically ill patients in intensive care units with vitamin D deficiency, vitamin D3 treatment has minimal health benefit, according to a study published online Sept. 30 in the Journal of the American Medical Association. The study was published to coincide with the annual meeting of the European Society of Intensive Care Medicine, held from Sept. 27 to Oct. 1 in Barcelona, Spain.
The start of the fall season means that around the country children are settling into their school routines. It also means cold and flu season is just around the corner, and with a particularly harsh winter predicted for parts of the country that could mean bad news for the end of 2014.
Adding the drug pertuzumab (Perjeta) to trastuzumab may give women with human epidermal growth factor receptor 2-positive metastatic breast cancer a boost in survival, according to new research presented Sunday at the annual meeting of the European Society of Medical Oncology, held from Sept. 26 to 29 in Madrid.
Obesity and inflammation in late adolescence are associated with increased risk for colon and rectal cancer in adulthood, according to a study presented at the American Association for Cancer Research's International Conference on Frontiers in Cancer Prevention Research, held from Sept. 28 to Oct. 1 in New Orleans.
Having trainee physicians review cases prior to clinic hours can reduce patient waiting times, flow times, and clinic session times, according to a study published online Sept. 16 in Pain Medicine. The management process studied was first popularized by Toyota in Japan.
More Reading